ERBB2 and breast carcinoma: In metastatic HER2-positive breast cancer, the NALA trial compared neratinib+capecitabine and lapatinib +capecitabine, which verified that patients who previously received at least two HER2-targeted treatments had extended PFS in the neratinib group, and no new safety signals were observed [64].